Biological Effects of Ultrasound Insonification of the Spleen
NCT ID: NCT03548116
Last Updated: 2021-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
137 participants
INTERVENTIONAL
2018-04-23
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The participants that clear study screening will be randomized to one of seven groups. The groups consist of: sham insonification at the hilum (connected probe or disconnected probe); half-powered insonification at the hilum; full-powered insonification at the hilum; sham insonification at the lower, middle, and upper spleen; half-powered insonification at the lower, middle, and upper spleen; and full-powered insonification at the lower, middle, and upper spleen.
At the baseline visit, individuals will be asked to undergo a physical and neurological examination and a blood draw of 7 teaspoons before receiving ultrasound as per their assigned group. These individuals will then be asked to undergo a blood draw of 5 teaspoons at 1-hour and 2-hours after the ultrasound.
Individuals will be asked to return 24 hours later for the follow-up visit, which will include a physical and neurological examination and a blood draw of 9 teaspoons.
The blood samples collected before insonification, one hour after insonification, two hours after insonification, and twenty-four hours after insonification will be assessed for changes in biomarkers (substances in the body that indicate the status of a biological process or condition). These biomarkers include cytokines (proteins involved in the immune response), norepinephrine (chemical in the body that transmits signals), glucose (sugar in the blood), and blood cells that are involved in breathing, clotting, and the immune response.
The study will be considered complete after completion of enrollment (10 participants in each group, for a study total of 70 participants), completion of study procedures by all participants, and the completion of analysis of identifiable study data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Sham Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Group 2
Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Group 3
Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Group 4
Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
Sham Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Group 5
Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Group 6
Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Group 7
Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Sham Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Sham Ultrasound
A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals without physical disabilities or conditions/diseases that may make them incapable of undergoing the study procedures or otherwise places them at a greater risk of harm
* Individuals without significant past medical or surgical histories that would render them at a greater risk of harm
* Individuals that are considered English Proficient due to the study requirements to follow verbal commands during the ultrasound session
* Individuals that are considered active as assessed by type of activity (i.e., walking, running, etc.) and number of hours a week performing the various activities
* Individuals able to attend all study visits at approximately the same time of day (i.e., 8 - 12 pm)
* Individuals that are able to comprehend the study goals and procedures, and are able to provide informed consent for participation
Exclusion Criteria
* Individuals considered substantially overweight or obese via body mass index (≥ 29)
* Individuals having or exhibiting any of the following:
* surgery in the past 90 days
* previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver
* recent traumatic injury, including intracerebral hemorrhage and visceral injury
* end stage renal disease and/or uremia
* active malignancy
* previous leukemia and/or lymphoma
* human immunodeficiency virus infection or AIDS
* rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease)
* arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, clinically significant bradycardia, ventricular arrhythmias, and A-V block
* implanted pacemaker or cardioverter/defibrillator (AICD)
* a history of stable or unstable angina, myocardial infarction, angioplasty or coronary arterial by-pass grafting surgery
* history of stroke or TIA
* history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE)
* previous episodes of pancreatitis
* spinal disorders
* chronic pain syndromes
* history of thrombosis or bleeding disorders
* stage III-IV pressure ulcers
* sickle cell anemia or other anemia syndromes
* monocytosis
* thrombocytopenia
* diagnosed with fever of unknown origin (FUO)
* previously or currently implanted vagus nerve stimulator
* previously or currently implanted spinal cord stimulator
* other chronically-implanted electronic medical device
* history of seizures
* history of cancer
* Individuals who have taken any of the following medications within one week of receiving ultrasound delivery:
* anti-coagulant (Coumadin, Xarelto)
* anti-platelet (aspirin, Plavix)
* anti-inflammatory (aspirin, NSAIDs)
* anti-hypertensive (α-methyldopa)
* epinephrine-related drugs, norepinephrine-related drugs, and drugs that stimulate release of epinephrine and/or norepinephrine (Micronefrin, Asthmanefrin)
* immunosuppressive agents (steroids, newer immunomodulatory drugs)
* alpha and/or beta adrenoceptor blocking agents
* anti-seizure medications
* other medications, supplements, etc. that may interfere with the ultrasound delivery or study results
* Individuals with a substance abuse (alcoholism or other) problem
* Individuals that consumed alcohol within 4 days of the baseline visit
* Individuals currently using or have used tobacco or nicotine products within the past 1 month
* Individuals currently using or have used recreational drugs within the past 1 month
* Pregnant women
* Prisoners
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General Electric
INDUSTRY
John Pellerito
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Pellerito
Vice Chairman of Education, Department of Radiology; Director, Peripheral Vascular Laboratory and the Body Imaging Fellowship Program
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Pellerito, MD
Role: PRINCIPAL_INVESTIGATOR
Northwell Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwell Health's The Feinstein Institute for Medical Research
Manhasset, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R, Tracey KJ, Tak PP. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9. doi: 10.1073/pnas.1605635113. Epub 2016 Jul 5.
Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, Lu YH, Kozlova A, Voss H, Martins GG, Friedman JM, Domingos AI. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell. 2015 Sep 24;163(1):84-94. doi: 10.1016/j.cell.2015.08.055.
Parker JL, Cameron T. Technology for Peripheral Nerve Stimulation. Prog Neurol Surg. 2015;29:1-19. doi: 10.1159/000434651. Epub 2015 Sep 4.
Birk DM, Yin D, Slavin KV. Regulation of Peripheral Nerve Stimulation Technology. Prog Neurol Surg. 2015;29:225-37. doi: 10.1159/000434674. Epub 2015 Sep 4.
Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007 Feb;117(2):289-96. doi: 10.1172/JCI30555.
Martelli D, McKinley MJ, McAllen RM. The cholinergic anti-inflammatory pathway: a critical review. Auton Neurosci. 2014 May;182:65-9. doi: 10.1016/j.autneu.2013.12.007. Epub 2013 Dec 24.
Juan EJ, Gonzalez R, Albors G, Ward MP, Irazoqui P. Vagus Nerve Modulation Using Focused Pulsed Ultrasound: Potential Applications and Preliminary Observations in a Rat. Int J Imaging Syst Technol. 2014 Mar 1;24(1):67-71. doi: 10.1002/ima.22080.
Goggins E, Inoue H, Okusa MD. Neuroimmune Control of Inflammation in Acute Kidney Injury and Multiorgan Dysfunction. J Am Soc Nephrol. 2025 Jul 7. doi: 10.1681/ASN.0000000813. Online ahead of print.
Related Links
Access external resources that provide additional context or updates about the study.
Stimulating Peripheral Activity to Relieve Conditions (SPARC)
Electrical Prescriptions
Ultrasonic Stimulation of Peripheral Nervous Tissue
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-0859
Identifier Type: -
Identifier Source: org_study_id